KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner
Year: 2019
Type: article
Abstract: Deregulation of KRAS4b signaling pathway has been implicated in 30% of all cancers. Membrane localization of KRAS4b is an essential step for the initiation of the downstream signaling cascades that guide various cellular mechanisms. KRAS4b plasma membrane (PM) binding is mediated by the insertion of a prenylated moiety that is attached to the terminal carboxy-methylated cysteine, in addition to electrostatic interactions of its positively charged hypervariable region with anionic lipids. Calmodulin (CaM) has been suggested to selectively bind KRAS4b to act as a negative regulator of the RAS/mitogen-activated protein kinase (MAPK) signaling pathway by displacing KRAS4b from the membrane. However, the mechanism by which CaM can recognize and displace KRAS4b from the membrane is not well understood. In this study, we employed biophysical and structural techniques to characterize this mechanism in detail. We show that KRAS4b prenylation is required for binding to CaM and that the hydrophobic pockets of CaM can accommodate the prenylated region of KRAS4b, which might represent a novel CaM-binding motif. Remarkably, prenylated KRAS4b forms a 2:1 stoichiometric complex with CaM in a nucleotide-independent manner. The interaction between prenylated KRAS4b and CaM is enthalpically driven, and electrostatic interactions also contribute to the formation of the complex. The prenylated KRAS4b terminal KSKTKC-farnesylation and carboxy-methylation is sufficient for binding and defines the minimal CaM-binding motif. This is the same region implicated in membrane and phosphodiesterase6-δ binding. Finally, we provide a structure-based docking model by which CaM binds to prenylated KRAS4b. Our data provide new insights into the KRAS4b-CaM interaction and suggest a possible mechanism whereby CaM can regulate KRAS4b membrane localization.
Source: Biophysical Journal
Institutions: Frederick National Laboratory for Cancer Research, National Cancer Institute, Leidos Biomedical Research Inc. (United States), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, University of Wisconsin–Madison, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $2,500
Funders: National Science Foundation, U.S. Department of Agriculture, University of Wisconsin-Madison, Frederick National Laboratory for Cancer Research, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources
Awards: G1653542590, G1849603858, WIDE-BORE 9.4 TESLA NMR SPECTROMETER FOR UW-MADISON, G2188346365, Upgrade of the NMRFAM 750 MHz NMR Spectrometer, G2941318404, G3005889490, G3443649240, G3503792436, G386607036, New Ways of Targeting K-Ras, National Biomedical NMR Resource at Madison, National Biological NMR Facility at Madison, G413875322, Integrated state-of-the-art LC-MS/NMR system for the University of Wisconsin, Development of 750 MHz Spectroscopy at the National Magnetic Resonance Facility at Madison., G4988656331, G5262810016, National Biomedical NMR Resource at Madison, CONSOLE UPGRADES FOR NMR FACILITY, NMR Spectrometer System Optimized for Direct 13C or 15N Detection, G5888954722, G6719958276, G8257980825, G8926230526
OpenAlex ID: W2913027519
